New cell therapy YTB323 targets MS that breaks through strongest drugs

NCT ID NCT06617793

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a single dose, and researchers monitor side effects, disability changes, and how the therapy behaves in the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site
RECRUITING

Montpellier, 34090, France
Novartis Investigative Site
RECRUITING

Nancy, 54035, France
Novartis Investigative Site
RECRUITING

Rennes, 35033, France
Novartis Investigative Site
RECRUITING

Bochum, 44791, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Mainz, 55131, Germany
Novartis Investigative Site
RECRUITING

Ulm, 89081, Germany
Novartis Investigative Site
RECRUITING

Genova, GE, 16132, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20132, Italy
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Córdoba, 14004, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28034, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain
Novartis Investigative Site
RECRUITING

Bern, 3010, Switzerland
Novartis Investigative Site
RECRUITING

Lausanne, 1011, Switzerland
Novartis Investigative Site
RECRUITING

Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.